Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06031441 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Metastatic Solid Tumors and Locally Advanced Solid Tumors, sponsored by Genentech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
- 18
- Study locations
NCT06031441 is a Phase 1 study of Metastatic Solid Tumors and Locally Advanced Solid Tumors that is actively recruiting participants, run by Genentech. The registered enrollment target is 250 participants, above the 194-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target (29% higher). The trial reports 18 study locations across 11 states.
The verdict
NCT06031441, a Phase 1 study of Metastatic Solid Tumors and Locally Advanced Solid Tumors, is actively recruiting participants, sponsored by Genentech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination with atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Participants will be enrolled in 2 stages: dose escalation and expansion.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG RO7566802
Study Locations (18)
Other
- National University Hospital - Singapore
- National Cancer Centre - Singapore
- Addenbrooke's Hospital - Cambridge
- Leicester Royal Infirmary - Leicester
- St Bartholomew's Hospital - London
- Sarah Cannon Research Institute - London
- Churchill Hospital - Oxford
- The Royal Marsden hospital - Sutton
Alabama
- University of Alabama at Birmingham (UAB) - Birmingham
Connecticut
- Yale Cancer Center - New Haven
New York
- Icahn School of Medicine at Mount Sinai (ISMMS) - New York
Ohio
- The Ohio State University - Columbus
Pennsylvania
- Magee-Woman's Hospital - Harrisburg
Tennessee
- SCRI Oncology Partners - Nashville
New South Wales
- St Vincent's Hospital Sydney - Darlinghurst
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06031441
The ClinicalTrials.gov registry entry for NCT06031441 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 194-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target (29% higher). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.
NCT06031441 reports 18 study locations spanning 11 distinct geographic areas - top geographies include Other, Alabama, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06031441 about?
NCT06031441 is a clinical study titled "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors". This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination with atezolizumab in participants ...
What is the current status of trial NCT06031441?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2023-11-27. Estimated completion is 2027-12-31.
What conditions does trial NCT06031441 study?
This clinical trial studies the following conditions: Metastatic Solid Tumors, Locally Advanced Solid Tumors, Recurrent Solid Tumors.
What interventions are being tested in trial NCT06031441?
The interventions under investigation include: Atezolizumab (DRUG), RO7566802 (DRUG).
Who is sponsoring clinical trial NCT06031441?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06031441 being conducted?
This trial has 18 study locations across Alabama, Connecticut, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
SLV-324 Treatment of Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
RECRUITING · Phase 1
-
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
RECRUITING · Phase 1
-
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.